Threshold Reports "Encouraging" Phase II Glufosfamide Data For Use With Gemzar
This article was originally published in The Pink Sheet Daily
Executive Summary
Initial safety analysis of pancreatic cancer trial shows a "slightly higher" incidence of nephrotoxicity with the combination regimen compared to individual use of either drug.